Abstract
Sequential evaluation of P-glycoprotein expression was performed in 29 patients with acute nonlymphoblastic leukemia using immunocytochemistry with the C219 antibody. At diagnosis, 32% of the patients exhibited more than 5% of the P-gp(+) leukemic cells. Under chemotherapy, 62% of the patients eventually expressed a subset of P-gp positive leukemic cells. After conventional doses of cytosine-arabinoside (Ara-C) and daunorubicin or mitoxantrone, positive P-gp cells were noted in 65% of the cases. This percentage was significantly higher (p = 0.002) than the proportion of positive cases (15%) observed after regimens containing either intermediate doses of Ara-C or cyclosporine A, a P-gp modulator.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
Adult
-
Aged
-
Amsacrine / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Female
-
Follow-Up Studies
-
Gene Expression Regulation, Leukemic*
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / genetics*
-
Male
-
Membrane Glycoproteins / biosynthesis*
-
Membrane Glycoproteins / genetics
-
Middle Aged
-
Mitoxantrone / administration & dosage
-
Neoplasm Proteins / biosynthesis*
-
Neoplasm Proteins / genetics
-
Remission Induction
Substances
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
Membrane Glycoproteins
-
Neoplasm Proteins
-
Amsacrine
-
Cytarabine
-
Mitoxantrone
-
Daunorubicin